© 2024 BioMarin. All rights reserved.

Back to Leadership

Brinda Balakrishnan, M.D., Ph.D., serves as Chief Corporate Strategy and Business Development Officer, with responsibility for the company’s corporate strategy, competitive intelligence, business development, alliance management organizations. She joined the company in early 2016.

Prior to joining BioMarin, Brinda was the co-founder and vice president of Corporate Strategy and Product Development at Vision Medicines, a startup focused on developing treatments for rare ophthalmic diseases, such as Stargardt disease. Earlier in her career, she was a consultant with McKinsey & Company’s healthcare practice. She began her industry career in business development at Genzyme Corporation.

Brinda has a B.S. in Chemical Engineering, Ph.D. in Biomedical Engineering and Chemical Engineering from the Massachusetts Institute of Technology, and an M.D. from Harvard Medical School with Internal Medicine training at the Beth Israel Deaconess Medical Center in Boston. Brinda is an independent director on the Board of Directors of Aurinia Pharmaceuticals.

Brinda is a runner, passionate about art and South Indian music, and enjoys spending every free moment with her husband, three sons and mother.

Our Pipeline

We maximize the impact of genetic innovation to develop transformative therapies.

Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.

Learn More Our Pipeline